Patents by Inventor Mohamed H. Sayegh

Mohamed H. Sayegh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeting ABCB5 for cancer therapy
    Patent number: 9855342
    Abstract: The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: January 2, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Markus H. Frank, Natasha Y. Frank, Mohamed H. Sayegh
  • Methods of modulating immunity
    Patent number: 9850305
    Abstract: The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: December 26, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Howard Weiner, Mohamed H. Sayegh
  • Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof
    Patent number: 9561264
    Abstract: The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: February 7, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Markus H. Frank, Mohamed H. Sayegh
  • TARGETING ABCB5 FOR CANCER THERAPY
    Publication number: 20160136297
    Abstract: The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.
    Type: Application
    Filed: January 25, 2016
    Publication date: May 19, 2016
    Applicant: The Brigham and Women's Hospital, Inc
    Inventors: Markus H. Frank, Natasha Y. Frank, Mohamed H. Sayegh
  • Targeting ABCB5 for cancer therapy
    Patent number: 9266946
    Abstract: The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: February 23, 2016
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Markus H. Frank, Natasha Y. Frank, Mohamed H. Sayegh
  • METHODS OF MODULATING IMMUNITY
    Publication number: 20150064197
    Abstract: The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Inventors: Howard Weiner, Mohamed H. Sayegh
  • TARGETING ABCB5 FOR CANCER THERAPY
    Publication number: 20140302031
    Abstract: The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.
    Type: Application
    Filed: April 14, 2014
    Publication date: October 9, 2014
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Markus H. Frank, Natasha Y. Frank, Mohamed H. Sayegh
  • Targeting ABCB5 for cancer therapy
    Patent number: 8697072
    Abstract: The invention related to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: April 15, 2014
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Markus H. Frank, Natasha Y. Frank, Mohamed H. Sayegh
  • Methods of Using Anti-Thymocyte Globulin and Related Agents
    Publication number: 20130344092
    Abstract: Novel uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-? are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at a low dose (e.g., less than 1 mg/kg per day) to treat an immune-mediated condition. The immune-mediated conditions include, for example, transplant rejection, graft-versus-host disease, and autoimmune diseases.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicants: The Brigham and Women's Hospital, Inc., Genzyme Corporation
    Inventors: Nader Najafian, Mohamed H. Sayegh, Melanie Ruzek, Srinivas Shankara, John Williams, Johanne Kaplan, John M. McPherson
  • GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF
    Publication number: 20130287785
    Abstract: The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.
    Type: Application
    Filed: July 10, 2013
    Publication date: October 31, 2013
    Inventors: Markus M. Frank, Mohamed H. Sayegh
  • Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof
    Patent number: 8507273
    Abstract: The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: August 13, 2013
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Markus H. Frank, Mohamed H. Sayegh
  • Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7P15-21 and uses thereof
    Patent number: 8425876
    Abstract: The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: April 23, 2013
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Markus H. Frank, Mohamed H. Sayegh
  • GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF (FRANK)
    Publication number: 20120034196
    Abstract: The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.
    Type: Application
    Filed: October 24, 2011
    Publication date: February 9, 2012
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Markus H. Frank, Mohamed H. Sayegh
  • Gene encoding a multidrug-resistance human P-glycoprotein homologue on chromosome 7P15-21 and uses thereof
    Patent number: 8076091
    Abstract: The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: December 13, 2011
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Markus H. Frank, Mohamed H. Sayegh
  • Methods of Modulating Immunity
    Publication number: 20110165177
    Abstract: The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.
    Type: Application
    Filed: December 30, 2010
    Publication date: July 7, 2011
    Applicant: BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Howard L. Weiner, Mohamed H. Sayegh
  • TARGETING ABCB5 FOR CANCER THERAPY
    Publication number: 20110165149
    Abstract: The invention related to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.
    Type: Application
    Filed: March 10, 2011
    Publication date: July 7, 2011
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Markus H. Frank, Natasha Y. Frank, Mohamed H. Sayegh
  • Targeting ABCB5 for cancer therapy
    Patent number: 7928202
    Abstract: The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: April 19, 2011
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Markus H. Frank, Natasha Y. Frank, Mohamed H. Sayegh
  • Methods of modulating immunity
    Patent number: 7883703
    Abstract: The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: February 8, 2011
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Howard L. Weiner, Mohamed H. Sayegh
  • GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF
    Publication number: 20100145030
    Abstract: The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.
    Type: Application
    Filed: February 9, 2010
    Publication date: June 10, 2010
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: MARKUS H. FRANK, MOHAMED H. SAYEGH
  • Methods of Using Anti-Thymocyte Globulin and Related Agents
    Publication number: 20100034782
    Abstract: Uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-beta are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at a low dose (e.g., less than 1 mg/kg per day) to treat an immune-mediated condition. The immune-mediated conditions include, for example, transplant rejection, graft-versus-host disease, and autoimmune diseases.
    Type: Application
    Filed: May 31, 2007
    Publication date: February 11, 2010
    Inventors: Nader Najafian, Mohamed H. Sayegh, Melanie Ruzek, Srinivas Shankara, John Williams, Johanne Kaplan, John M. McPherson